查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1718304

乾眼症治療市場按藥物類型、產品形式、活性成分、作用機制、通路和使用者概況分類－2025-2030 年全球預測

Dry Eye Medication Market by Drug Type, Product Form, Active Ingredient, Mode of Action, Distribution Channel, User Profile - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計乾眼症藥物市場規模到 2024 年將達到 48.6 億美元，到 2025 年將達到 51.8 億美元，到 2030 年將達到 71.9 億美元，複合年成長率為 6.72%。

主要市場統計數據
基準年2024年 48.6億美元
預計2025年 51.8億美元
預測年份 2030 71.9億美元
複合年成長率（%） 6.72%

乾眼症藥物市場已發展成為一個先進的生態系統，匯集了尖端研究、對眼部生理學的深入了解以及不斷成長的患者群體。最近的技術突破和改進的臨床指南正在推動這一演變。生物技術和藥物配方的進步為解決乾眼症的症狀和根本原因的更有效治療方法鋪平了道路。人們對這種疾病的醫療保健意識不斷增強，並且越來越多的醫療專業人員了解如何治療乾眼症，這導致人們對更有效的治療方法的興趣日益濃厚。

這個充滿活力的市場不再局限於傳統治療方法。相反，包括新型眼藥水和輔助性治療在內的藥物傳輸技術創新正在不斷改變治療通訊協定。因此，製造商和製藥公司現在專注於開發平衡療效和患者舒適度的綜合治療方法。科學研究與實際臨床應用的結合正在為該領域的投資和成長創造新的機會。

此外，這種市場演變反映了全球醫療保健行業的更廣泛趨勢，即以患者為中心的方法帶來更個人化的治療。現在使用增強的診斷工具和數位監控系統來根據患者的個別需求量身定做治療方案，確保每個療程都以細緻的數據主導洞察為基礎。個人化護理和先進治療方案的結合意味著治療乾眼症症狀的前景光明。

改變乾眼症治療市場

在過去的十年中，乾眼症藥物領域發生了變革，重新定義了臨床應用和策略市場定位。這種變化的主要驅動力是更加重視實證治療、長期緩解眼部症狀的需求以及致力於改善患者的生活品質。藥物傳遞系統的創新意味著治療劑能夠更精確地到達目標組織，確保製劑能如預期發揮作用，同時最大限度地減少副作用。

目前，治療方法明顯趨向多學科化，將傳統方法與現代創新結合。製藥公司正在採用自適應臨床試驗設計來加快新療法的測試和核准。法規環境逐漸變得更容易接受創新測試結果，從而鼓勵快速的開發和實施週期。

隨著成熟公司和新興企業紛紛投資研發，這些進步與數位監控工具的使用相輔相成，提高了病患的參與度和遵從性。科技在完善以患者為中心的策略、加強診斷和後續護理過程以及最終推動市場成長方面發揮關鍵作用。不斷發展的市場繼續推動行業領導者不斷創新，以確保功效和安全性仍然是產品設計的首要考慮因素。

此外，學術界、生技公司和大型製藥公司之間的合作正在為研究樹立新的標竿。這些合作不僅擴大了科學知識基礎，也促進了實驗室發現更順利地轉化為臨床應用。隨著臨床試驗的進行和真實世界證據的積累，這些合作正在產生足夠的動力來重新定義乾眼症治療的治療模式。

影響市場演變的關鍵細分洞察

乾眼症藥物市場的細分為其結構和未來方向提供了重要的見解。根據藥物類型進行的分析顯示，重點關注兩種選擇：非處方藥和處方藥，強調了可近性與個人化治療性介入介入需求之間的平衡。檢查產品形式可以發現多樣化的產品組合，包括眼藥水、眼瞼濕紙巾、凝膠、藥膏和噴霧劑，每種產品都能滿足特定的臨床要求和患者偏好。

基於活性成分的進一步分析提供了更細緻的理解。羧甲基纖維素等成分可增加潤滑作用，而Cyclosporine和利菲特斯特等成分可作為強大的免疫調節劑來對抗發炎。聚乙二醇也因其支持治療方法的獨特特性而受到認可。包括作用機制在內的層次細分同樣富有洞察力。該市場透過整合抗發炎劑、免疫調節劑、潤滑劑和促分泌劑來實現差異化。這不僅凸顯了疾病的複雜性，也凸顯了應用多面向治療策略的重要性。

分銷通路研究進一步將市場分為醫院藥局、網路藥局和電子商務平台以及傳統零售藥局。每個管道都對市場動態和消費者訪問做出了獨特的貢獻。此外，考慮成人、老年人和兒科的使用者資料細分突顯了針對不同年齡層進行客製化治療方法的必要性，確保滿足特定的人口需求。這種全面的細分框架使相關人員能夠制定和部署直接滿足全球乾眼症患者群體多樣化需求的策略。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 全球乾眼症盛行率不斷上升
      • 提高消費者對眼睛健康的認知和積極的自我護理行為
      • 擴大醫療基礎設施並改善眼科保健服務的可近性
    • 限制因素
      • 患者依從性與長期療效問題
    • 機會
      • 加強研發夥伴關係，加速創新週期
      • 擴展電子商務平台，提供乾眼症藥物的全球訪問和個人化解決方案
    • 任務
      • 遵守各地區的嚴格規定
  • 市場區隔分析
    • 產品形式：眼瞼濕紙巾，用於去除刺激物並減輕患者的炎症
    • 分銷管道：為了應對監管挑戰並滿足日益成長的消費者需求，網路藥局越來越受歡迎。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章 乾眼症治療市場（依藥物類型）

  • 非處方藥
  • 處方藥

第7章 乾眼症治療市場（依產品類型）

  • 眼藥水
  • 眼瞼擦拭
  • 凝膠
  • 軟膏
  • 噴

第 8 章 乾眼症治療市場（依活性成分）

  • 羧甲基纖維素
  • Cyclosporine
  • 利菲特格拉斯特
  • 聚乙二醇

第9章 乾眼症治療市場（依作用機轉）

  • 抗發炎劑
  • 免疫調節藥物
  • 潤滑劑
  • 分泌者

第 10 章 乾眼症治療市場（依通路）

  • 醫院藥房
  • 網路藥局/電子商務平台
  • 零售藥局

第11章 乾眼症治療市場（依使用者概況）

  • 成人
  • 老年病學
  • 小兒科

12.美洲乾眼症藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

13. 亞太地區乾眼症藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

14.歐洲、中東和非洲乾眼症藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • AbbVie Inc.
  • Alcon Inc.
  • Astellas Pharma Inc.
  • Bausch+Lomb Corporation
  • EyeGate Pharmaceuticals, Inc.
  • Harrow Health, Inc.
  • Johnson & Johnson Services, Inc.
  • Kala Pharmaceuticals, Inc.
  • Kowa Company, Ltd.
  • Laboratorios Sophia SA De CV
  • Merck & Co., Inc.
  • Mitotech SA
  • Nicox SA
  • Novartis AG
  • Ocugen, Inc.
  • Ocular Therapeutix, Inc.
  • Optix Pharmaceuticals, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Perrigo Company plc
  • Pfizer Inc.
  • Rohto Pharmaceutical Co., Ltd.
  • Santen Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Viatris Inc.
  • Wockhardt Ltd. by Dr. Reddy's Laboratories
Product Code: MRR-1A1A064C0036

The Dry Eye Medication Market was valued at USD 4.86 billion in 2024 and is projected to grow to USD 5.18 billion in 2025, with a CAGR of 6.72%, reaching USD 7.19 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 4.86 billion
Estimated Year [2025] USD 5.18 billion
Forecast Year [2030] USD 7.19 billion
CAGR (%) 6.72%

The dry eye medication market has evolved into a sophisticated ecosystem that brings together cutting-edge research, a deeper understanding of ocular physiology, and an expanding patient demographic. Recent technological breakthroughs combined with enhanced clinical guidelines have catalyzed this evolution. Advances in biotechnology and pharmaceutical formulations have paved the way for more effective therapies that address both the symptomatic and underlying causes of dry eye disease. Increasing awareness of the condition and a growing base of healthcare professionals trained in its management have driven further interest in improved therapeutic options.

This dynamic market is no longer confined to traditional remedies. Instead, a blend of innovation in drug deliveries, such as novel eye drops and adjunct therapies, continuously reshapes treatment protocols. As a result, manufacturers and pharmaceutical companies are now placing an emphasis on the development of comprehensive treatment regimens that balance efficacy with patient comfort. The integration of scientific research with practical clinical applications has created new opportunities for investment and growth within the sector.

Furthermore, the market's evolution reflects wider trends in the global healthcare industry where patient-centric approaches are leading to more personalized therapy. Enhanced diagnostic tools and digital monitoring systems are now being used to tailor treatments to individual patient needs, ensuring that each therapy course is backed by meticulous data-driven insights. This integration of personalized care and advanced therapeutic options signifies a promising future for the management of dry eye conditions.

Transformative Shifts in the Dry Eye Medication Landscape

Over the past decade, the dry eye medication landscape has undergone transformative shifts that have redefined both clinical applications and strategic market positioning. These changes are primarily driven by an increased focus on evidence-backed treatments, a demand for prolonged relief, and a dedication to enhancing patient quality of life. Innovation in drug delivery systems now means that therapies reach the target tissues with improved precision, ensuring that formulations work as intended, while minimizing side effects.

There is a clear movement towards a multi-disciplinary treatment approach that encompasses integration between traditional methodologies and modern innovation. Pharmaceutical companies have embraced adaptive clinical trial designs to expedite the testing and approval of novel therapies. The regulatory environment has gradually become more accommodating to innovative trial results, thereby fostering a rapid cycle of development and implementation.

As both established and emerging companies invest in research and development, the use of digital monitoring tools to increase patient engagement and adherence has complemented these advancements. Technology has played a crucial role in refining patient-centric strategies, enhancing the diagnosis and follow-up care process, and ultimately driving market growth. The market's evolution continues to prompt industry leaders to innovate relentlessly, ensuring that both efficacy and safety remain top priorities in product design.

Moreover, partnerships between academia, biotechnology firms, and pharmaceutical giants are setting new benchmarks for research. These alliances are not only expanding the scientific knowledge base but are also facilitating a smoother transition from laboratory findings to clinical application. As ongoing clinical trials and real-world evidence accumulate, this collaborative spirit is generating sufficient momentum to redefine treatment paradigms in the management of dry eye disease.

Key Segmentation Insights Shaping Market Evolution

The segmentation of the dry eye medication market offers critical insights into its structure and future direction. Analysis based on drug type reveals a dual focus between over-the-counter medications and prescription options, highlighting a balance between accessibility and the need for tailored therapeutic interventions. An examination of the product form reveals a diverse portfolio that includes eye drops, eye lid wipes, gels, ointments, and sprays, each addressing specific clinical requirements and patient preferences.

Further analysis based on active ingredients provides an even more nuanced understanding. Ingredients such as carboxymethylcellulose offer enhanced lubrication, while others like cyclosporine and lifitegrast serve as potent immunomodulatory agents addressing inflammation. Polyethylene glycol is also recognized for its unique properties that support the therapeutic regimen. The layered segmentation that includes the mode of action is equally insightful. The market distinguishes itself by integrating anti-inflammatory agents, immunomodulatory agents, lubricating agents, and secretagogues. This not only underscores the complexity of the disease but underlines the importance of applying multifaceted treatment strategies.

The survey of the distribution channel further stratifies the market into hospital pharmacies, online pharmacies and e-commerce platforms, and traditional retail pharmacies. Each of these channels contributes uniquely to market dynamics and consumer access. Additionally, the user profile segmentation, which considers adults, geriatrics, and pediatrics, highlights the need for therapies that are tailor-made for diverse age groups, ensuring that specific demographic needs are met. This comprehensive segmentation framework enables stakeholders to develop and deploy strategies that directly address the multifarious requirements of the global dry eye patient community.

Based on Drug Type, market is studied across Over-The-Counter Medication and Prescription Medication.

Based on Product Form, market is studied across Eye Drops, Eye Lid Wipes, Gels, Ointments, and Sprays.

Based on Active Ingredient, market is studied across Carboxymethylcellulose, Cyclosporine, Lifitegrast, and Polyethylene Glycol.

Based on Mode of Action, market is studied across Anti-Inflammatory Agents, Immunomodulatory Agents, Lubricating Agents, and Secretagogues.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies/E-commerce Platforms, and Retail Pharmacies.

Based on User Profile, market is studied across Adults, Geriatrics, and Pediatrics.

Critical Regional Insights Across Key Markets

A detailed regional analysis reveals significant geographic disparities in market activity and patient needs. In the Americas, a proactive approach to healthcare combined with robust insurance frameworks has spurred widespread acceptance of innovative therapies. Clinical trial activity and consumer awareness in this region have reinforced the importance of treatment customization, encouraging ongoing investment in pharmaceutical research.

In the combined region of Europe, Middle East and Africa, diverse economic realities and heterogeneous healthcare systems challenge manufacturers to adapt their strategies to local demands. While regulatory frameworks in Europe promote innovation, emerging markets in the Middle East and Africa are gradually aligning with global standards. The need for affordable yet effective treatments is driving cost-efficient innovations, thereby opening new economic avenues and niche segments that are poised for growth.

The Asia-Pacific region represents a rapidly evolving market where large populations, an increasing prevalence of dry eye conditions, and rising disposable incomes are coalescing to reshape market dynamics. Growing awareness and improved access to healthcare have generated demand for specialized therapeutic solutions. Innovations are being rapidly adopted as local manufacturers seek to address regional patient needs by aligning their products with both traditional and modern medicinal approaches. Each region's unique characteristics and requirements highlight an intricate balance between innovation, patient education, and the need for cost-effective solutions.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Company-Level Strategies Driving Competitive Advantages

The competitive landscape in the dry eye medication market is both diverse and dynamic, with a large number of influential players each carving out a niche in this evolving field. Major pharmaceutical companies like AbbVie Inc., Alcon Inc. and Astellas Pharma Inc. have strategically positioned themselves through extensive research and robust clinical portfolios, setting high benchmarks for quality and efficacy. Equally prominent, industry stalwarts such as Bausch + Lomb Corporation have continually leveraged their experience to stay ahead in an ever-changing market.

Innovative smaller companies including EyeGate Pharmaceuticals, Inc. and Harrow Health, Inc. are redefining segments through niche product offerings and agile market strategies. Additionally, the strong industry presence maintained by Johnson & Johnson Services, Inc. further accentuates a competitive landscape that thrives on both innovation and scale. Emerging players such as Kala Pharmaceuticals, Inc. and the multifaceted approach of Kowa Company, Ltd. and Laboratorios Sophia S.A. De C.V. contribute to an environment where strategic partnerships and relentless product development are the norms.

Other well-known entities, notably Merck & Co., Inc. and Mitotech S.A., have committed significant resources to research endeavors aimed at addressing unmet clinical needs. Companies like Nicox S.A. and Novartis AG exemplify the balance between traditional pharmaceutical expertise and modern therapeutic innovation. The market is further enriched by contributions from Ocugen, Inc., Ocular Therapeutix, Inc., and Optix Pharmaceuticals, Inc. which offer distinct treatment modalities. In addition, industry giants such as Otsuka Pharmaceutical Co., Ltd., Perrigo Company plc, and Pfizer Inc. have deepened their focus on the development of dry eye medications through targeted research.

The innovative initiatives by Rohto Pharmaceutical Co., Ltd. and Santen Pharmaceutical Co., Ltd., along with the expansive reach of Sun Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited, continue to redefine competitive frameworks. Other notable players such as Viatris Inc. and Wockhardt Ltd. bolster a competitive landscape that is marked by diversity and continuous innovation. Collectively, these companies illustrate a market where strategic research, expansive distribution networks, and a commitment to product excellence drive the future of dry eye medications.

The report delves into recent significant developments in the Dry Eye Medication Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alcon Inc., Astellas Pharma Inc., Bausch + Lomb Corporation, EyeGate Pharmaceuticals, Inc., Harrow Health, Inc., Johnson & Johnson Services, Inc., Kala Pharmaceuticals, Inc., Kowa Company, Ltd., Laboratorios Sophia S.A. De C.V., Merck & Co., Inc., Mitotech S.A., Nicox S.A., Novartis AG, Ocugen, Inc., Ocular Therapeutix, Inc., Optix Pharmaceuticals, Inc., Otsuka Pharmaceutical Co., Ltd., Perrigo Company plc, Pfizer Inc., Rohto Pharmaceutical Co., Ltd., Santen Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Viatris Inc., and Wockhardt Ltd. by Dr. Reddy's Laboratories. Actionable Recommendations for Industry Leaders in Dry Eye Therapy

For industry leaders within the dry eye medication market, strategic decision-making is essential to remain competitive and meet the emerging needs of patients. Leaders should consider investing in advanced research initiatives that target both the symptomatic and underlying causes of dry eye disease. A robust commitment to innovation-encompassing not only novel molecules but also breakthrough delivery systems-will be critical in meeting evolving patient expectations.

Optimizing clinical trial frameworks should also remain a priority. By adopting adaptive clinical trials and leveraging digital health technologies for patient monitoring and data collection, companies can accelerate the time-to-market for new formulations. Regulatory harmonization across key markets is another aspect that can streamline the introduction of new therapies. Establishing collaborations with leading academic institutions and technology firms can further accelerate the pace at which innovations are brought to market.

In addition, tailoring treatments to meet the specific needs of diverse patient segments is of paramount importance. This involves a comprehensive understanding of division by drug type, with formulations that range in their application from over-the-counter solutions to prescription-based treatments. Emphasizing personalized patient care means investing in targeted therapies that consider both product form and active ingredient efficacy. Equally, integration of mode of action insights into product development strategies-incorporating mechanisms such as anti-inflammatory and immunomodulatory effects-can lead to more holistic treatment offerings.

Distribution efficiency is another critical area. Ensuring that products are readily available across hospital pharmacies, online platforms, and retail outlets will foster greater accessibility for patients. In parallel, aligning production strategies with the latest shifts in user profiles-catering to adults, geriatrics, and pediatrics-will be essential for long-term market growth. By embracing technological advancements, fostering partnerships, and committing to patient-centric solutions, industry leaders can harness emerging opportunities and mitigate existing challenges, thus reinforcing their competitive posture in an increasingly dynamic marketplace.

Conclusive Insights on Market Dynamics

In summary, the current landscape of dry eye medication is marked by both impressive innovation and increasing competition. A detailed examination of the market reveals persistent advancements in drug technology, shifts in regulatory standards, and diversification of therapeutic options. Through deliberate segmentation analysis, it is evident that a multifaceted approach-one that considers drug type, product formulation, and active ingredients-drives the development of more effective treatment regimens. Furthermore, evaluating the roles of mode of action, distribution channels, and user profiles provides a comprehensive framework that informs both product development and market strategy.

Industry players must remain vigilant in their pursuit of excellence by adopting agile approaches and aligning their research and development with emerging market trends. The integration of precision medicine, digital health, and robust data analytics stands as a testament to the potential for meaningful transformation in the sector. As market dynamics continue to evolve, companies that are both innovative and responsive to change will be best positioned to capture a larger share of the global market while improving overall patient outcomes.

This advanced understanding of market segmentation, regional dynamics, and competitive strategies ultimately forms the groundwork for strategic growth and sustainable competitive advantage. Embracing these insights will empower the industry to address current challenges and seize the multitude of opportunities that lie ahead.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of dry eye syndrome globally
      • 5.1.1.2. Rising consumer awareness about ocular health and proactive self-care behaviors
      • 5.1.1.3. Expanding healthcare infrastructure and improved access to ophthalmic services
    • 5.1.2. Restraints
      • 5.1.2.1. Patient compliance and long-term efficacy issues
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising partnerships in research and development to enable faster innovation cycles
      • 5.1.3.2. Expansion of e-commerce platform for global access and personalized solutions in the dry eye medication
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory compliances across different region
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Forms: Adoption of eye lid wipes to remove irritants and reducing inflammation in patients
    • 5.2.2. Distribution Channel: Growing preference for online pharmacies to address regulatory challenges and meet expanding consumer demands
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Dry Eye Medication Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Over-The-Counter Medication
  • 6.3. Prescription Medication

7. Dry Eye Medication Market, by Product Form

  • 7.1. Introduction
  • 7.2. Eye Drops
  • 7.3. Eye Lid Wipes
  • 7.4. Gels
  • 7.5. Ointments
  • 7.6. Sprays

8. Dry Eye Medication Market, by Active Ingredient

  • 8.1. Introduction
  • 8.2. Carboxymethylcellulose
  • 8.3. Cyclosporine
  • 8.4. Lifitegrast
  • 8.5. Polyethylene Glycol

9. Dry Eye Medication Market, by Mode of Action

  • 9.1. Introduction
  • 9.2. Anti-Inflammatory Agents
  • 9.3. Immunomodulatory Agents
  • 9.4. Lubricating Agents
  • 9.5. Secretagogues

10. Dry Eye Medication Market, by Distribution Channel

  • 10.1. Introduction
  • 10.2. Hospital Pharmacies
  • 10.3. Online Pharmacies/E-commerce Platforms
  • 10.4. Retail Pharmacies

11. Dry Eye Medication Market, by User Profile

  • 11.1. Introduction
  • 11.2. Adults
  • 11.3. Geriatrics
  • 11.4. Pediatrics

12. Americas Dry Eye Medication Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Dry Eye Medication Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Dry Eye Medication Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Ocumension entered into an agreement with Alcon to expand China's dry eye treatment portfolio
    • 15.3.2. Novaliq and Laboratoires Thea partner to launch Vevizye in Europe
    • 15.3.3. Nordic Pharma launch LACRIFILL Canalicular gel for dry eye therapy
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alcon Inc.
  • 3. Astellas Pharma Inc.
  • 4. Bausch + Lomb Corporation
  • 5. EyeGate Pharmaceuticals, Inc.
  • 6. Harrow Health, Inc.
  • 7. Johnson & Johnson Services, Inc.
  • 8. Kala Pharmaceuticals, Inc.
  • 9. Kowa Company, Ltd.
  • 10. Laboratorios Sophia S.A. De C.V.
  • 11. Merck & Co., Inc.
  • 12. Mitotech S.A.
  • 13. Nicox S.A.
  • 14. Novartis AG
  • 15. Ocugen, Inc.
  • 16. Ocular Therapeutix, Inc.
  • 17. Optix Pharmaceuticals, Inc.
  • 18. Otsuka Pharmaceutical Co., Ltd.
  • 19. Perrigo Company plc
  • 20. Pfizer Inc.
  • 21. Rohto Pharmaceutical Co., Ltd.
  • 22. Santen Pharmaceutical Co., Ltd.
  • 23. Sun Pharmaceutical Industries Ltd.
  • 24. Takeda Pharmaceutical Company Limited
  • 25. Viatris Inc.
  • 26. Wockhardt Ltd. by Dr. Reddy's Laboratories

LIST OF FIGURES

  • FIGURE 1. DRY EYE MEDICATION MARKET MULTI-CURRENCY
  • FIGURE 2. DRY EYE MEDICATION MARKET MULTI-LANGUAGE
  • FIGURE 3. DRY EYE MEDICATION MARKET RESEARCH PROCESS
  • FIGURE 4. DRY EYE MEDICATION MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL DRY EYE MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 23. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. DRY EYE MEDICATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 29. DRY EYE MEDICATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. DRY EYE MEDICATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL DRY EYE MEDICATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DRY EYE MEDICATION MARKET DYNAMICS
  • TABLE 7. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY OVER-THE-COUNTER MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PRESCRIPTION MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY EYE DROPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY EYE LID WIPES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SPRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY CARBOXYMETHYLCELLULOSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY CYCLOSPORINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY LIFITEGRAST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY POLYETHYLENE GLYCOL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ANTI-INFLAMMATORY AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY LUBRICATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY SECRETAGOGUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ONLINE PHARMACIES/E-COMMERCE PLATFORMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL DRY EYE MEDICATION MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES DRY EYE MEDICATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA DRY EYE MEDICATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM DRY EYE MEDICATION MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM DRY EYE MEDICATION MARKET SIZE, BY PRODUCT FORM, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM DRY EYE MEDICATION MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM DRY EYE MEDICATION MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM DRY EYE MEDICATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM DRY EYE MEDICATION MARKET SIZE, BY USER PROFILE, 2018-2030 (USD MILLION)
  • TABLE 284. DRY EYE MEDICATION MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 285. DRY EYE MEDICATION MARKET, FPNV POSITIONING MATRIX, 2024